Pharmacological basis for duration of effect: Formoterol and salmeterol versus short-acting beta(2)-adrenoceptor agonists

被引:0
|
作者
Linden, A
Rabe, KF
Lofdahl, CG
机构
[1] GOTHENBURG UNIV, SAHLGRENS HOSP, DIV PULM MED, S-41345 GOTHENBURG, SWEDEN
[2] KRANKENHAUS GROSSHANSDORF, LANDESVERSICHERUNGANSTALT HAMBURG, ZENTRUM PNEUMOL & THORAXCHIRURG, D-22927 GROSSHANSDORF, GERMANY
关键词
airway smooth-muscle relaxation; beta(2)-adrenoceptor agonists; bronchodilator; duration of action; exosite; formoterol; microkinetic diffusion; salmeterol; BETA-ADRENOCEPTOR AGONISTS; AIRWAY SMOOTH-MUSCLE; GUINEA-PIG TRACHEA; BETA-2-ADRENOCEPTOR AGONIST; FUNCTIONAL ANTAGONISM; SALBUTAMOL; RELEASE; BAMBUTEROL; INVITRO; ASTHMA;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The mechanisms behind the long duration of bronchodilating action of the beta(2)-adrenoceptor agonists formoterol and salmeterol are only partially understood, This review compares pharmacological characteristics of long-acting versus short-acting beta(2)-adrenoceptor agonists in human and animal airways. Based upon the reviewed evidence, it is concluded that for beta(2)-adrenoceptor agonists, long duration of action may depend upon several factors, Both formoterol and salmeterol display a higher lipophilicity and have a higher affinity, selectivity, and potency than most short-acting agonists at the beta(2)-adrenoceptor. Of these factors, lipophilicity may prove to be one of the most important ones by determining the amount of drug entering into the cell membrane in the vicinity of the beta(2)-adrenoceptor. However, the receptor affinity, maximal relaxant effect (efficacy or intrinsic activity), potency, and receptor selectivity may also be of importance in determining how much beta(2)-adrenoceptor agonist must remain at the receptor for sustained action.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 50 条
  • [41] Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children
    Griffiths, Benedict
    Ducharme, Francine M.
    PAEDIATRIC RESPIRATORY REVIEWS, 2013, 14 (04) : 234 - 235
  • [42] Use of short-acting beta-2 agonists (SABA) and exacerbations in a nationwide Swedish asthma cohort (HERA)
    Janson, Christer
    Nwaru, Brigth
    Hasvold, Lars Pal
    Wicklund, Fredrik
    Telg, Gunilla
    Ekstrom, Magnus
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [43] Use of short-acting beta2-agonists during pregnancy and the risk of pregnancy-induced hypertension
    Martel, M. J.
    Rey, E.
    Beauchesne, M. F.
    Perreault, S.
    Forget, A.
    Maghni, K.
    Lefebvre, G.
    Blais, L.
    JOURNAL OF WOMENS HEALTH, 2007, 16 (06) : 928 - 928
  • [44] Novel short-acting A2A adenosine receptor agonists for coronary vasodilation:: Inverse relationship between affinity and duration of action of A2A agonists
    Gao, ZH
    Li, ZH
    Baker, SP
    Lasley, RD
    Meyer, S
    Elzein, E
    Palle, V
    Zablocki, JA
    Blackburn, B
    Belardinelli, L
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 298 (01): : 209 - 218
  • [45] Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children
    Griffiths, Benedict
    Ducharme, Francine M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (08):
  • [46] Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports
    Dobek, Rafal
    Barg, Wojciech
    Bochenek, Grazyna
    Brozek, Grzegorz
    Brzostek, Dorota
    Dabrowiecki, Piotr
    Dabrowski, Andrzej
    Gawlik, Radoslaw
    Kucharczyk, Aleksandra
    Kuprys-Lipinska, Izabela
    Mastalerz-Migas, Agnieszka
    Zagrajek, Edyta
    Kowalski, Marek L.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [47] THE EFFECTS OF FORMOTEROL, A LONG-ACTING BETA(2)-ADRENOCEPTOR AGONIST, ON MUCOCILIARY ACTIVITY
    LINDBERG, S
    KHAN, R
    RUNER, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 285 (03) : 275 - 280
  • [48] Differential effects of short-acting β2-agonists on human granulocyte functions
    Yasui, K
    Kobayashi, N
    Yamazaki, T
    Agematsu, K
    Matsuzaki, S
    Nakata, S
    Baba, A
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2006, 139 (01) : 1 - 8
  • [49] ADVERSE EVENTS OF AS-NEEDED INHALED CORTICOSTEROID AND FORMOTEROL VERSUS SHORT ACTING BETA2 AGONISTS IN ASTHMA EXACERBATIONS: A META-ANALYSIS
    Elises Ogbac, Martin Kristoffer
    Dizon, Rodolfo V.
    RESPIROLOGY, 2019, 24 : 199 - 200
  • [50] Short-acting β2-agonists and greenhouse gas emissions in Europe and Canada
    Janson, Christer
    Maslova, Ekaterina
    Wilkinson, Alexander
    Penz, Erika
    Papi, Alberto
    Budgen, Nigel
    Vogelmeier, Claus F.
    Kupczyk, Maciej
    Bell, John
    Menzies-Gow, Andrew
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58